Eprenetapopt indicated for the treatment of TP53 Mutant Acute Myeloid Leukemia (AML)... Dec 02
Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548 ... Oct 08
-Advertisements-